DENOSUMAB-GCTB-LT

NCT00680992 📎

Regimen

Experimental
Denosumab 120 mg SC Q4W long-term (often with treatment interruptions)
Control
none (long-term single-arm)

Population

Combined pooled GCTB cohort (surgically unsalvageable + salvageable with severe morbidity) with extended follow-up through ~5 years of denosumab

Key finding

Durable, years-long disease control confirmed in the largest GCTB denosumab dataset. Safety signal (ONJ, atypical fractures) clarified for long-term dosing, informing current practice of treatment interruptions and holiday schedules.

Source: PMID 31704134

Timeline

    Guideline citations

    • NCCN BONE (p.20)